UK markets open in 7 hours 44 minutes
  • NIKKEI 225

    27,509.46
    0.00 (0.00%)
     
  • HANG SENG

    21,660.47
    -297.93 (-1.36%)
     
  • CRUDE OIL

    73.54
    +0.15 (+0.20%)
     
  • GOLD FUTURES

    1,878.50
    +1.90 (+0.10%)
     
  • DOW

    33,926.01
    -127.89 (-0.38%)
     
  • BTC-GBP

    19,089.04
    -406.77 (-2.09%)
     
  • CMC Crypto 200

    535.42
    -1.43 (-0.27%)
     
  • ^IXIC

    12,006.96
    -193.84 (-1.59%)
     
  • ^FTAS

    4,339.71
    +36.82 (+0.86%)
     

Freeline Reports December 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc

LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on December 30, 2022, the Company granted four newly hired employees non-statutory options to purchase an aggregate of 48,900 of the Company’s ordinary shares.

The awards were granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by an independent subcommittee of the remuneration committee of Freeline’s board of directors. The awards were granted pursuant to the terms of Freeline’s 2021 Equity Inducement Plan, which was adopted by Freeline’s board of directors in September 2021.

Each of the options has an exercise price of $0.47 per share, which was the closing price of Freeline’s American Depositary Shares reported by Nasdaq on December 29, 2022, the last trading day preceding the grant date. The options have a maximum 10-year term and vest over a four-year service period, with 25% of the award vesting on the first anniversary of the vesting commencement date, with the balance vesting monthly over the remaining three years.

About Freeline Therapeutics
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies. The company is dedicated to improving patient lives through innovative, one-time treatments for chronic debilitating diseases. Freeline uses its proprietary, rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream. The company is advancing clinical programs in Fabry disease and Gaucher disease Type 1. Freeline is headquartered in the UK and has operations in Germany and the U.S.

Media and Investor Contact:

Naomi Aoki
naomi.aoki@freeline.life
Senior Vice President, Head of Investor Relations & Communications
+ 1 617 283 4298